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Abstract 
Human immunodeficient virus (HIV) is a retrovirus that cause acquired 
immunodeficiency syndrome (AIDS). Highly active antiretroviral therapy (HAART) is 
a treatment of HIV infection that uses combinations of antiretroviral drugs and has 
achieved great success in the past two decades. However, since the reverse transcription 
process of viral RNA is notoriously prone to error, HIV-1 can acquire resistance to 
nearly all known inhibitors and has started to develop resistance to HAART. Therefore, 
there is an ongoing search for new drugs with novel inhibitory mechanism such as 
targeting cellular proteins essential for HIV-1 replication to overcome drug resistance of 
the virus. 
HIV-1 mRNA undergoes complex splicing and the expression of the integrated 
HIV-1 provirus is largely dependent on the host’s splicing machinery which assembly 
requires splicing factors such as serine-arginine rich proteins (SR proteins). Alternative 
splicing factor/splicing factor 2 (ASF/SF2), a prototypic SR protein that is essential for 
pre-mRNA splicing, has been shown to play critical roles during HIV-1 pre-mRNA 
splicing and replication. ASF/SF2, like other SR proteins, is phosphorylated by SR 
protein-specific kinases (SRPKs) at its C-terminal arginine/serine (RS) domain, which 
governs its localization and metabolism. Structural and functional studies of SRPK1 in 
complex with ASF/SF2 has revealed that a docking groove on SRPK1 that is distal to 
the active site interacts strongly with a docking motif and the RS domain of ASF/SF2, 
leading to high affinity binding as well as regulating the mechanism of phosphorylation. 
 I
In this study, we propose that by blocking this interaction, we might interfere the 
phosphorylation of ASF/SF2 and inhibit its activity during splicing of HIV-1 
pre-mRNA.  
Structure-based in silico screening method is adopted to identify potential inhibitors 
that bind to the docking groove of SRPK1 to block the binding and phosphorylation of 
ASF/SF2. The compound libraries being used include the Natual Products Database and 
SPECS database from ZINC (UCSF). 351,473 compounds have been screened using the 
program Autodock Vina as well as Autodock 4.0. Until now 50 potential candidates of 
inhibitor have been selected for biochemical analyses. In vitro kinase assays showed 
that six compounds exhibit inhibitory activity against the phosphorylation of ASF/SF2. 
To test the effect of the selected inhibitors on the splicing of HIV-1 mRNA, ex vivo 
splicing assay has been performed. Current results showed that the synthesis of splicing 
products extracted from drug-treated cells was less efficient when compared to 
untreated cells. Biological assays testing the inhibitory effects of the compounds on 
viral infection are currently underway. Our preliminary result suggested that one of the  
compounds could indeed inhibit HIV-1 viral infection. 
Other biochemical and biological analyses including structural study of 
kinase-inhibitor complexes to understand the mode of inhibition; measurement of 
binding kinetics using surface plasmon resonance spectroscopy (SPR); and biological 
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Chapter : IntroductionⅠ  
 
 1
1.1 HIV, HAART and HIV Drug Resistance 
Human immunodeficiency virus (HIV) is a lentivirus (a member of the retrovirus 
family) that causes acquired immunodeficiency syndrome (AIDS) (Weiss, 1993). It is 
an enveloped virus (Figure 1.1) which envelope is derived from the host cell membrane 
and contains viral glycoproteins such as gp120 and gp41 that are inserted into the 
membrane as the virus leaves the cell. Inside the core are two identical copies of 
single-stranded RNA viral genome and three enzymes: reverse transcriptase, protease 
and integrase. To establish infection, HIV must first attach to its host cell. Attachment 
occurs when gp120 interacts with CD4 antigen receptor on the surface of the host cell 
with the help of different co-receptors (Chan and Kim, 1998). Then the viral envelop 
and the host cell membrane fuses, resulting in the entry of the virus into the cell (Wyatt 
and Sodroski, 1998). The viral RNA genome of HIV is then released into the cytoplasm 
of the host cell. The viral reverse transcriptase makes a DNA copy of the viral RNA 
genome  (Zheng et al., 2005) and the DNA is then transported into the nucleus and 
inserted into the host cell chromosome by the viral integrase enzyme, forming the 
proviral DNA. Transcription of the proviral DNA is carried out by the host cell’s 
transcription machinery and the newly synthesized viral mRNA is then translated, 
yielding viral enzymes and structural proteins that are required for the packaging of new 
virus particles. Some of these functional proteins are formed by cleavage of long 
poly-proteins by the viral protease. Finally, the virion is released from the host cell by 




Figure 1. 1 Structure of HIV-1 virus (http://en.wikipedia.org/wiki/File:HIV_gross_ 
cycle_only.png). The virol envelope is derived from the host cell membrane with viral 
glycoproteins such as gp120 and gp41 inserted into the lipid bilayer. Inside the core are 
two identical copies of single-stranded RNA viral genome and three enzymes, reverse 








Figure 1. 2 The HIV replication cycle (http://en.wikipedia.org/wiki/File: HIV_ gross 
_cycle_only.png). Firstly, to establish infection, HIV attaches to its host cell through 
interaction with CD4-receptor. Then the viral envelope and the host cell membranes 
fuse, resulting in the entry of the virus into the cell. After the RNA is released into the 
cytoplasm of the host cell, reverse transcriptase makes a DNA copy of the viral RNA 
genome, which is later inserted into the host cell chromosome by integrase. After 
translation, some of the functional protein is formed by cleavage of a long poly-protein 
by the viral protease. Finally, the fully assembled virion is released by budding.
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According to the estimations made by the World Health Organization (WHO) in 2011, 
about 33.3 million people are living with HIV. The growth rate of the total number of 
HIV infections has slowed down since the beginning of 21st century; meanwhile, the 
number of the AIDS-related deaths also falls rapidly. The reduction in AIDS-related 
deaths is mostly contributed by the significant scale up of antiretroviral therapy over the 
past few years (figure 1.3) (WHO Progress report, 2011). 
In particular, highly active antiretroviral therapy (HAART), which is introduced in 
1997 uses combinations of antiretroviral drugs for the treatment of HIV infection 
(Gelderblom, 1997). Currently, drugs being used in HAART to treat HIV-1 infection 
could be classified into five distinct classes: entry inhibitors, nucleoside and nucleotide 
analogues, nonnucleoside reverse transcriptase inhibitors, integrase inhibitors and 
protease inhibitors. Entry inhibitors aim to block HIV viron from penetrating into the 
target cells by interfering with the interactions between gp120 and host cells’ receptors  
(Dybul et al., 2002). Nucleoside and nucleotide analogues act as DNA-chain 
terminators and inhibit the reverse transcription of the viral RNA genome into DNA; 
while nonnucleoside reverse-transcriptase inhibitors bind and inhibit the viral reverse 
transcriptase directly. Integrase inhibitors block the integration. Finally, protease 
inhibitors are designed to inhibit the proteolytic activity of the viral protease that is 
essential for viral particles assembly. 
The usual HAART regimen combines three or more different drugs such as two 
nucleoside reverse transcriptase inhibitors (NRTIs) and a protease inhibitor (PI), two 
NRTIs and a non-nucleoside reverse transcriptase inhibitor (NNRTI) or other similar 
 5
  
Figure 1. 3 Number of people with access to antiretroviral therapy and the number of 
people dying from AIDS-related causes (WHO Progress report, 2011). 
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combinations. These HAART regimens, commonly known as cocktail therapy, have 
proven to reduce the amount of active viruses in patients and in some cases to an extent 
where it is undetectable by current blood testing techniques (Henkel, 1999). 
However, HAART is not bullet-proof and sometimes HIV drug resistance is 
acquired by viral mutation that promotes virus replication even in the presence of 
antiretroviral drugs, leading to antiretroviral therapy (ART) failure, consequently the 
spread of resistant strains of HIV and the need to develop new anti-HIV drugs (Geretti, 
2006). The increasing prevalence of drug resistance compromised the benefits of the use 
of HAART and challenges the remarkable treatment of HIV-1-infected patients (Barbaro 
et al., 2005; del Rio, 2006). 
As mentioned, HIV is a retrovirus which genome consists of RNA. By using 
reverse transcriptase, HIV virus synthesizes DNA from its single-strand RNA genome 
through a reverse transcription (RT) process that lacks a mechanism for correcting 
errors made while copying its genome (Freeman, 2007). The reverse transcription of 
viral RNA into DNA is notoriously prone to error, introducing on average one mutation 
for each viral genome transcribed, resulting that HIV replicates its genome with the 
highest known mutation rate of any pathological agents (Freeman, 2007). These 
mutations accumulate and lead to great genetic variation within populations of virus, 
while creating an ideal situation and raw material for natural selection over generations 
(Freeman, 2007). Selected virions with higher fitness would survive (Kozal, 2009), 
resulting in drug resistance virions that escape the harmful effects of anti-HIV drugs, 
which then reproduce and create an entirely new, drug resistant population. An 
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investigation report by WHO in 2004 estimated 76.3% of HIV-positive population in 
USA is suffering with some form of drug resistance (Richman et al., 2004). 
Due to drug resistance caused by the error-prone reverse transcription process, 
different mechanisms have also been characterized for individual class of drug or even 
for drugs from the same class.  
For instance, non-nucleoside reverse-transcriptase inhibitors work as potent and 
highly selective inhibitors of HIV-1 reverse transcriptase. These small molecules bind 
to the less conserved hydrophobic pocket located near the active site in the p66 
subdomain of the reverse transcriptase with strong affinity. By interfering the flexibility 
of the enzyme, the drugs subsequently distort its ability to bind RNA and block DNA 
synthesis (Esnouf et al., 1997). However, mutations could occur through selection in the 
targeted pocket after prolonged treatment with the nonnucleoside reverse transcriptase 
inhibitors. These drugs then lose their specific interactions with their targeted docking 
pocket (Boyer et al., 1993). In particular, resistance to the treatment with a combination 
of efavirenz (EFV) and nevirapine (NVP), both belong to the non-nucleoside reverse 
transcriptase inhibitors, is typically associated with the mutations L100I, Y181C/I, 
K103N, V106A/M, V108I, Y188C/H/L and G190A/S on the reverse transcriptase. 
The treatment regimens of HIV/AIDS currently used in HARRT are mainly 
targeting the viral specific enzymes and proteins, such as reverse transcriptase, protease, 
and gp120. Because of multidrug-resistant, toxic side effects, poor patient compliance 
due to complicated regimens，there is an immediate need for the search of new drugs 
with novel inhibitory mechanism to overcome drug resistance of the virus. For instance, 
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apart from the targeted viral-specific proteins, various cellular proteins also play critical 
roles during HIV-1 replication. Research on these essential host cell factors might 
provide the basis for the development of novel drugs that target cellular proteins that are 
not affected by the HIV-1 reverse transcription process, thus block the replication of the 
HIV-1 virus on the premise to reduce the burden of spread of multidrug-resistant 
HIV-1.  
 
1.2 HIV-1 alternative splicing mechanism 
After the HIV-1 genome is reverse transcribed and integrated into the host cell 
genome, a primary transcript of 9 kb pre-mRNA is transcribed from the integrated viral 
DNA by RNA polymerase II. This primary transcript serves as genomic RNA for 
progeny virus and the mRNA that encodes the viral Gag and Pol proteins. However, 
more importantly, the transcripts contains multiple splicing sites and generates over 40 
different spliced mRNAs by alternative splicing (McLaren et al., 2008). HIV-1 
pre-mRNA splicing is a highly orchestrated process by which the virus regulates proper 
cytoplasmic levels of both spliced mRNAs for viral protein synthesis and unspliced 
viral RNA to serve as both genome RNA as well as mRNA for translation. 
Over the past two decades, there is significant progress on the study of mechanisms 
on how HIV-1 regulates its pre-mRNA splicing (Lutzelberger et al., 2006b; Pollard and 




Figure 1. 4 Schematic organisation of the HIV-1 genome and different mRNA splicing 
products. HIV-1 5’splice sites (D1, D2, D3 and D4) and 3’ splice sites (A1, A2, A3, 
A4c,a,b, A5 and A7) are indicated. The various open reading frames of the 
HIV-1 genome are denoted by different coloured boxes. 
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(in the 5' to 3' direction), which denominate the 5’ splice donor (Figure 1.4 D1–D4) and 
3’ splice acceptor site (Figure. 1.4, A1–A7) respectively. These consensus splice site 
sequences are usually required for the recognition by the cellular spliceosome during 
constitutive splicing (Lutzelberger et al., 2006a). 
To express all key viral proteins, HIV-1 uses a combination of several alternative 5′ 
and 3′ splice sites to generate two sorts of spliced mRNA species that can be classified 
as multiply spliced (~2 kb) and singly spliced (~ 4 kb) RNAs (Fig. 1.4) (Purcell and 
Martin, 1993). Five 3’ss (A3, A4c, A4a, A4b and A5) serve as the splice acceptor sites 
for the multiply spliced mRNA to produce mRNAs for Tat, Rev, or Nef proteins 
respectively during the early stage of HIV-1 gene expression.  Sort of Tat 
(trans-activator of transcription) mRNA uses the A3 splice site, while the Nef (negative 
regulatory factor) mRNAs are spliced at site A5 (Stoltzfus and Madsen, 2006). On the 
other hand, the Rev (regulator of virion expression) mRNAs are spliced respectively at 
sites A4a, A4b or A4c. Only when these splice sites are utilized accurately during 
alternative splicing that the encoded functional proteins can be expressed and support 
the viral life cycle of HIV-1. The main function of Tat proteins is to extensively increase 
the level of transcription of the HIV dsRNA and plays a more direct role in the HIV 
disease process. The expression of Nef modulates T cell activation and ensures a 
persistent state of infection. Nef also facilitates the survival of host cells by 
down-modulating the expression of several surface molecules to satisfy the 
requirements of the HIV-1 viral life cycle. The Rev protein, a product of the doubly 
spliced mRNA, facilitates the expression of HIV proteins by controlling the export rate 
 11
of singly and unspliced mRNAs from nuclear to cytoplasm (Kim et al., 1989; Klotman 
et al., 1992). Completely spliced mRNAs like Rev in general will be translated in the 
cytoplasm first because they are smaller and exported faster. Therefore, Rev is 
particularly important in the regulation the expression of, the Gag and Gag-Pol 
polyproteins, as well as Vif, Vpr, Vpu and Env proteins by up-regulating the nuclear 
export of the incompletely spliced mRNAs that encode them. 
The process of alternative splicing is tightly regulated by a system of cis- and 
trans-regulatory elements. In HIV virus, the choice of alternative splice sites is 
dependent on the presence of cis-regulatory elements termed exonic splicing enhancers 
(ESEs) and/or exonic⁄intronic splicing silencers (ESS ⁄ ISS) on the pre-mRNA due to the 
weak 3′ ss (Caputi and Zahler, 2002; Staffa and Cochrane, 1994; Tange et al., 2001). 
ESEs and ESSs bind with trans-acting cellular splicing regulatory factors, which either 
promote or inhibit the splicing at neighbouring splice sites, respectively (Zahler A.M. et 
al., 2004). Some of these trans-acting factors include members of the serine-arginine 
rich protein (SR protein) and heterogenous nuclear ribonucleoproteins (hnRNPs) 
families. During alternative splicing of HIV-1 pre-mRNA, members of the hnRNP 
family play a role in the downregulation of splicing at the 3’ss A1 (Kammler et al., 
2006), A2  (Bilodeau et al., 2001), and A3 (Caputi et al., 1999; Jacquenet et al., 2001). 
On the other hand, binding of the SR proteins to exonic splicing enhancers (ESEs) can 
activate splicing at the 3’ss A2, A3, A5 and A7 (Zhu et al., 2001) 
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Since, both SR proteins and hnRNP families play crucial roles in the HIV-1 
pre-mRNA splicing and consequently important for viral propagation, these proteins 
thus represent potential drug targets for the development of antiretroviral therapies. 
1.3 SR Protein Family 
Serine/arginine-rich proteins (SR proteins) constitute a family of splicing factor 
that is involved in the regulation of constitutive splicing and also influences the 
selection of the alternative splice sites during alternative splicing in eukaryotic mRNA. 
The first SR protein was identified by Mark Roth in 1990 and this family of proteins 
was given the name SR proteins because they contain long repeats of serine and 
arginine dipeptide at their C-terminal regions (Madhani and Guthrie, 1994; Sharp, 
1994). 
The primary structures of all SR proteins follow the consensus that they either 
contain one or two N-terminal RNA-recognition motif (RRMs; also known as an RNA 
recognition domain [RBD]), and a C-terminal region enriched in different lengths of 
Arg–Ser dipeptides (Fu and Maniatis, 1992; Zahler et al., 1992). To date, 12 human SR 
proteins have been identified and classified as classical SR proteins. They are listed in 
Table 1.1. 
Based on the number of RRM(s), these 12 SR proteins could be further classified 
into two different groups. Group 1 proteins, consisting of SFRS1, SFRS4, SFRS5, 
SFRS6, and SFRS9, have two RRMs and contain a conserved SWQDLKD motif in  
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Table 1. 1: SR protein / gene symbol 
Previous gene symbol Aliases New protein/gene symbol 
SFRS1 ASF/SF2, SRP30a SRSF 1 
SFRS2 SC35, PR264, SRp30b SRSF 2 
SFRS3 SRp20 SRSF 3 
SFRS4 SRp75 SRSF 4 
SFRS5 SRp40, HRS SRSF 5 
SFRS6 SRp55, B52 SRSF 6 
SFRS7 9G8 SRSF 7 
SFRS2B SRp46 (human only) SRSF 8 
SFRS9 SRp30c SRSF 9 
SFRS13A TASR1, SRp38, SRrp40 SRSF 10 
SFRS11 P54, SRp54 SRSF 11 







Figure 1. 5 Human SR protein family. The schematic representations of the structural 
organization of nine human SR proteins are shown. RRM abbreviated for RNA 
recognition motif; RS, arginine/serine-rich domain; Zn, zinc finger. 
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their second non-canonical RRM. In comparison, group 2 SR proteins, which include 
SFRS13A, SFRS11, SFRS2B, SFRS2, SFRS3, SFRS7, and SFRS13B, contain only a 
single RRM and lack the SWQDLKD motif (Figure 1.5) (Manley and Krainer, 2010). 
While the N-terminal RRMs are responsible for sequence-specific RNA binding, 
the RS domains of SR proteins are believed to function as a protein-RNA and 
protein-protein interaction domain. The RS domain likely mediates interaction with 
other splicing proteins including other SR proteins, SR-related proteins(Blencowe et al., 
1999), and components of the general splicing machinery  (Kohtz et al., 1994; Wu and 
Maniatis, 1993), to enhance the assembly of the spliceosome (Fetzer et al., 1997; 
Makarova et al., 2001; Teigelkamp et al., 1997). Furthermore, the RS domain also 
participates in a nuclear localization pathway by mediating the interaction between the 
SR proteins and the β-karyopherin family member transportin-SR (Caceres et al., 1997; 
Kataoka et al., 1999; Lai et al., 2000). 
SR proteins predominantly locate in the nucleus (Cowper et al., 2001; Sakashita 
and Endo, 2010). A subset of SR proteins, like ASF/SF2, 9G8 and SRP20, shuttle 
continuously between the cytoplasm and the nucleus at a high dynamic rate with the 
help of transportin-SR (Caceres et al., 1997; Caceres et al., 1998b), which contacts with 
the RS domains to convey the SR proteins through the nuclear pore in a 
phosphorylation-dependent manner (Koizumi et al., 1999; Ngo et al., 2005) . 
 
1.4 Functional roles of SR protein in HIV pre-mRNA splicing 
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In general cases, SR proteins are essential for both the 5’ and 3’ splice sites 
selection in alternative splicing as well as stabilizing interactions between components 
of the splicing machinery during constitutive splicing. During alternative splicing, SR 
proteins usually recognize and bind to the exonic splicing enhancers (ESEs) and act as 
general activators of exon definition (Hertel et al., 1997; Lam and Hertel, 2002), which 
then regulate the recruitment of the splicing machinery to the adjacent splice sites. This 
process is mediated by at least one member of the SR protein family (Black, 2003; 
Blencowe, 2000; Graveley, 2000).  
Based on the conservation of the splicing pattern in different HIV expressing cells 
(Purcell and Martin, 1993), splicing of viral pre-mRNA must be tightly regulated and is 
crucial to the HIV virus life cycle (Gorry et al., 1999; Sonza et al., 2002). In fact, SR 
proteins ASF/SF2, SC35, 9G8 and SRp40 have been proven to play active roles in 
mediating the balance in the HIV-1 splicing pattern in vitro and ex vivo  (Mayeda et al., 
1999; Zahler et al., 2004). For instance, the expression levels of Env mRNA, Nef 
protein synthesis and full-length viral RNA decrease obviously when the SR proteins 
ASF/SF2, SC35 and SRP40 are overexpressed. Such disturbed viral RNA splicing 
pattern would lead to weaker virus infectivity and SR proteins overexpression can 
induce the inhibition of virion production (Jacquenet et al., 2005). Among all the splice 
sites in the HIV-1 pre-mRNA transcript, splice sites A1 and A2 are specifically activated 
by ASF/SF2 although site A1 is less sensitive to the regulation. Previous studies have 
shown that binding between the SR protein ASF/SF2 and ESE1 activates the HIV 
splicing at the A2, while hnRNP A⁄B represses this process (Calarco et al., 2009; 
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Nakagawa et al., 2005; Papoutsopoulou et al., 1999). As a result, overexpression of 
ASF/SF2 increases the level of Vpr mRNA specifically at the cost of the reduction of 
other mRNA species. On the other hand, SC35 and SRp40 strongly activate site A3 and 
their overexpression results in an accumulation of tat mRNA and disturbance of the 
splicing of other viral mRNAs (Ropers et al., 2004). These results suggest that individual 
SR proteins might have specific roles during the splicing of HIV-1 pre-mRNA and their 
levels must be tightly regulated in order for HIV-1 to complete its life cycle. 
Beside Site A2, Splice site A5, which is utilized for the production of singly 
spliced Env mRNA is also regulated by SF/ASF2. SF2 ⁄ASF functions as a trans-acting 
factor for the ESE sequence upstream of D4 and the ESE3 sequence as well (Dagher 
and Fu, 2001; Lim and Burge, 2001) (Table 1.2). Furthermore, HIV-1 3’ss A7 is 
negatively regulated by the ISS, ESS3 and ESE3. ESE3 actually functions as both 
splicing silencer and enhancer activities, for it can interact with both hnRNP A1 and 
SF2 ⁄ASF (Colwill et al., 1996b; Nieratschker et al., 2009; Wang et al., 1999).  
 
1.5 Phosphorylation States of SR Proteins 
SR proteins undergo dynamic phosphorylation and dephosphorylation during the 
pre-mRNA splicing process (Xiao and Manley, 1998). Phosphorylation of SR proteins 
has been well documented to occur in the C-terminal RS domain. Different 
phosphorylation states of SR protein regulate how the SR protein functions during the  
 18
 Table 1. 2: Summary of concerning regulatory sites and the regulatory factors 
involved 
3’ splicing site Regulatory elements 
regulatory factors 
involved position 






























assembly of spliceosome, splicing, and export of mRNA (Caceres et al., 1997; Hedley et 
al., 1995). RS domain phosphorylation also regulates the subcellular localization of SR 
proteins (Figure 1.6). SR proteins predominantly reside in nuclear speckles that serve as 
the sites for storage and/or reassembly of splicing factors. Hyperphosphorylation of the 
RS domain causes redistribution of SR proteins from nuclear speckles to the 
nucleoplasm and recruit them to the splicing sites (Lai et al., 2001). Furthermore, as 
aforementioned, some members of the SR protein family like ASF/SF2 continuously 
shuttle between the nucleus and the cytoplasm in a phosphorylation dependent manner 
(Caceres et al., 1998a). 
In fact, the nuclear import of SR proteins mediated by transportin-SR has been 
shown to depend on the phosphorylation state of the SR protein. Hypophosphorylation 
of the RS domain by the SR protein kinase SRPK1 drastically enhances the binding 
affinity between the SR proteins and transportin-SR (Lai et al., 2000). Thus, 
phosphorylation plays a key role in the regulation of the biological functions of SR 
proteins and subsequently splicing. 
 
1.6 SR protein Kinase 
Several protein kinases have been reported to phosphorylate multiple serines in the 
RS domain of SR proteins, including the SR protein kinase (SRPK) family, Cdc2-like 
kinase/Ser-Thr-Tyr (Clk/Sty) kinase family, DNA topoisomerase I and Akt (Blaustein et 
al., 2005; Colwill et al., 1996a; Gui et al., 1994; Rossi et al., 1996). Serine-arginine 
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Figure 1. 6 Regulation of SR protein localization by SRPK.  
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 protein kinases (SPRKs) predominantly phosphorylate SR proteins in vivo and alter 
their cellular distribution and activities. Members of SRPKs family are highly 
RS-specific kinases and have been shown to phosphorylate serine, but not threonine 
residues, that are immediately adjacent to arginine, but not lysine residues in vitro (Gui 
et al., 1994). Furthermore, biochemical and structural research on SRPK1 and Sky1p 
have provided evidence that SRPKs are constitutively active kinases (Ngo et al., 2007a; 
Nolen et al., 2001). These proteins, when purified from E.coli, are fully catalytically 
active in vitro and do not need any post-translational modification (Cao and 
Garcia-Blanco, 1998;Papoutsopoulou et al., 1999). 
The first serine-arginine (SR) protein kinase, SRPK1, was characterized and 
purified in 1994 (Lai et al., 2000). In 1998, the cloning and the characterization of 
SRPK2, which is highly related to SRPK1 in kinase core sequence, were performed 
(Kuroyanagi et al., 1998). Another member of SRPKs, SRPK1a, which is encoded by 
an alternative spliced SRPK1 transcript that retains 171 amino acids at its N-terminal 
domain, was reported in 2001 (Nikolakaki et al., 2001). Finally, mouse SRPK3 was 
identified as a downstream target gene of the transcription factor myocyte enhancer 
factor 2 (MEF2) in 2005 and was shown to specifically expressed in the heart and 
skeletal muscle (Nakagawa et al., 2005). Another Porcine SRPK3 gene encoding a 566 
amino acid protein was isolated in 2011 (Xu et al., 2011). 
SRPKs have been proven to phosphorylate more than ten members from the SR 
protein family both in vitro and in vivo. By influencing the phosphorylation states and 
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the localization of these SR proteins, it is suggested that SRPKs may indicatively 
regulate multiple facets of cell cycle, including mRNA maturation, cell cycle 
progression, chromatin reorganization and metabolic signaling. 
 
1.7 Interaction between SRPK1 and ASF/SF2 
ASF/SF2 (human alternative splicing factor) is the most well-studied member of 
the SR protein family. It comprises two RRM domains (RRM1 and RRM2) and a 
C-terminal RS domain. The RS domain of ASF/SF2 contains 20 serines where 15 of 
which are directly adjacent to arginine residues.  It has been shown that SR protein 
kinase 1 (SRPK1) phosphorylates approximately 12 of serines in the RS domain using a 
directional (C-terminal-to-N-terminal) and processive mechanism. 
The crystal structure of SRPK1ΔNS1, an active truncation of human SRPK1 with 
41 amino acids from the N terminus and the spacer residues (aa 256–473) deleted, has 
been solved in complex with a 9 mer peptide (RRR1E2R3S4P5T6R7) derived from an 
SR-like protein Npl3p (Figure 1.7) (Ngo et al., 2005). The structure reveals that 
SRPK1ΔNS1 shares the bilobal fold similar to other protein kinases. The small lobe is 
composed mostly of β-strands while the larger lobe is mostly -helical. SRPK1, 
belonging to the CMGC group of kinases, contains a mitogen-activated protein kinase 
(MAPK) insert that connects helices G and H. This MAP kinase insert, together with 
the loop connecting helices αF and αG, and the helix αG of the kinase region form a 
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docking groove that is distal to the active site of the kinase and interacts with the soaked 
RS peptide. Further biochemical studies on the function of this docking groove revealed 
that it is essential to the interaction between SRPK1 and ASF/SF2, and is responsible 
for mediating the processive phosphorylation of ASF/SF2. 
X-ray structure of another truncation construct of SRPK1, which includes residues 
69–235 and 475–655, in complex with the core binding domain of ASF/SF2, comprises 
the RRM2 and part of the RS domain (residues 121–196 and 201–210 respectively), 
reveals more structural features that are important for the interaction between the kinase 
and substrate and the mechanism of the phosphoralation (Ngo et al., 2008). Most 
importantly, this structure confirms that the docking groove of SRPK1 binds to 
arginine-rich peptide (derived from the RS domain) and is critical for the interaction and 
processive phosphorylation of ASF/SF2 (Ngo et al., 2008). This process of processive 
phosphorylation finally directs ASF/SF2 to be transported into the nucleus; whereas 
interference of the kinase-substrate interaction results in aberrant phosphorylation, 




 MAP kinase insert 
αF 
αG
Figure 1. 7 Docking groove of SRPK1. Surface rendition of SRPK1 bound to ASF/SF2. 
The observed peptide is the RS1 domain of ASF/SF2, which binds to a groove formed 
by helices αG, αF and the MAP kinase insert of SRPK1.  
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1.8 IDC16 and SPRIN340 
It is clear that members of the SR protein family play an essential role in the 
regulation of HIV-1 pre-mRNA splicing, implying that they could be potential drug 
targets for HIV-1. In 2007, Jamal Tazi and his team have shown proof that targeting 
HIV-1 splicing pathway could be a new approach of antiretroviral therapies. The team 
discovered a series of benzopyridoindole and pyridocarbazole derivatives that hinder 
the ESE dependent splicing activity of HIV virus (Bakkour et al., 2007).    
After further screening of a large database of chemical compounds, the same team 
found an indole derivative compound (IDC16) that interferes with the exonic splicing 
enhancer activity of ASF/SF2. In an ex vivo splicing assay, IDC16 inhibits the use of 
several weak 3’splice sites of HIV and less splicing products were produced when 
treated with IDC16. This, subsequently leads to suppression of the key vital proteins 
and compromises the assembly of infectious particles. Furthermore, IDC16 can 
efficiently block HIV-1 viral production in macrophage and T cell tropic laboratory 
strains, or several strains with high multi-resistance to the treatment of HAART. 
Compared with HAART that targets essential viral proteins, this is a totally different 
approach where cellular factors used by the virus are being targeted and has the great 
likelihood to overcome drug resistance. 
Besides inhibitors that directly target SR proteins,  Hagiwara’s group has reported 
an SR protein phosphorylation inhibitor 340 (SRPIN340), which is an isonicotinamide 
compound, that preferentially inhibits SRPK1 and SRPK2 and down-regulates the 
expression of SRp75, which is essential for HIV expression. SRp75 downregulates 
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splicing at the 5′splice site of exon 3 of HIV-1 mRNA, thereby resulting in dramatically 
increased level of vpr mRNA (Fukuhara et al., 2006). In addition to its potential 
function in HIV-1 inhibition, SRPIN340 has also been shown to interfere with the 
propagation of Sindbis virus in a plaque assay.  
These findings together suggest that targeting host cellular proteins like SRPKs 
and SR proteins to inhibit HIV-1 pre-mRNA splicing might provide alternative 
therapies to overcome drug resistance developed from genetic variation during virus 
reproduction.  
 
1.9 Structure-based drug screening 
Drug designing is the inventive approach for developing new medications 
according to the known biological target (Liljefors, et al., 2002). Due to the rapid need 
for new drugs to combat emerging diseases, more and more combinational techniques, 
including computer modeling techniques, are developed to speed up and lower the cost 
of the drug discovery process. Detailed structural information on protein-protein or 
protein-ligand interactions obtained through biophysical methods such as x-ray 
crystallography or NMR spectroscopy could provide structural basis to assist the drug 
discovery process. Based on the knowledge of the three-dimensional structure of the 
biomolecules, one can adopt the structure-based drug design approach to search for 
small molecules that target the potential biological receptors. This method has become 
one of the mainstreams in medicinal chemistry after rapid development of both 
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computation software and hardware in the past twenty years. Computer graphics, virtual 
screening, automated process of crystallography and other multi-facet techniques all 
play essential roles in the rapidly developing field of structure-based drug discovery.  
Virtual, or in silico, drug screening has occupied the main position at the early 
stage for new drug discovery in recent years. Well performed virtual screening using 
drug-like compound libraries is said to achieve about 1%-10% active compounds in real 
biological assay, while the probability using traditional methods with random library is 
estimated to be about 0.01% (Doman et al., 2002; Woodward et al., 2006).  
Structure-based virtual screening is a methodology that is widely used today 
(Kroemer, 2007). Structure-based screening predicts how the tested compound docks to 
the target protein 3D structure, by computing and evaluating the free binding energy 
between the protein and compound. In structure-based drug screening, small molecules 
from databases are virtually docked into selected site of the target protein through a 
docking program, which theoretically models the ligand–protein interaction to achieve 
an optimal complementarity of steric and physicochemical properties. A mathematical 
algorithm (also referred to as scoring function) will help to identify the utmost docking 
position on a targeted protein. Then compounds are ranked after the docking process 
and selected on the basis of some user-defined criteria, like suitable structure, charge, 
and binding affinity. Only a small part of top-ranked compounds will be chosen as 
candidates for later experimental assays to reduce the cost of the drug discovery process. 
Such structure-based virtual screening method has great success in the discovery of 
inhibitors for different targets, such as the SH2 domain of the proto-oncogene 
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tyrosine-protein kinase Src which is implicated in the treatment of osteoporosis and 
other bone-related diseases (Huang et al., 2004). 
 
1.10 AutoDock Suite 
One of the most adopted virtual screening software in the research community is 
AutoDock. AutoDock is a suite of molecular modeling simulation software developed 
by the Olson Laboratory at Scripps Research institute, La Jolla. As an effective 
automated docking tool for protein-ligand docking, AutoDock is designed to predict the 
critical interaction between the small molecules and biomacromolecules with known 3D 
structure. Until 2009, about 1200 publications have cited using the AutoDock method. 
So far, the discovery of several drugs is owed to AutoDock, including the most famous 
well-known HIV-1 integrase inhibitor Isentress. 
Currently, AutoDock suite contains two generations of docking software: 
AutoDock Vina and AutoDock 4. In the docking program AutoDock Vina, the search 
and optimization algorithm being used is termed iterated local search global optimizer. 
It does not take into account the atomic charges of the targets being tested but instead 
depends only on the atom types that are defined using an internal atom typing scheme. 
The scoring function is based on a machine learning approach trained against both 
conformation and affinity of the bound structure-ligand complex.  The combination of 
these two algorithm results in a significant gain in performance which, in large part, due 
to the use of a gradient optimization method that gives it a "sense of direction" from a 
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single evaluation.  
The other program AutoDock 4 uses a genetic algorithm that is based on natural 
evolution. Genetic algorithms employ a population of individuals that undergo selection 
in the presence of variation-inducing operators and a fitness function is used to evaluate 
individuals, and reproductive success varies with fitness. The results from AutoDock 4 
are given as estimates of free-energy change upon ligand binding and as a prediction of 
the ligand-receptor complex three-dimensional conformation.  
 Since AutoDock 4 and AutoDock Vina use different scoring functions, it is not 
completely appropriate to directly compare the accuracy of the results predicted by the 
programs. Either program may provide a better docking result for a particular protein 
target, despite AutoDock Vina performs two orders of magnitude faster than AutoDock 
4. Therefore, the two programs are chosen to be used in tandem in my project to 
improve our chance of finding true hits. 
 
1.11 Kinase-substrate interaction inhibitors 
Protein kinases are highly regulated enzymes that modify their substrates by 
transferring the terminal phosphate group of ATP to them. The human 
genome comprises about 518 protein kinase genes, constituting about 2% of all human 
genes (Manning et al., 2002). Up to 30% of all human proteins undergo phosphorylation 
by specific kinases at some point in their lifetime, which in turn mediate the majority of 
cellular pathways like gene expression and cell growth. 
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All protein kinases share a conserved bi-lobed kinase core structure (Stout et al., 
2004). Between the two lobes is a deep cleft where Mg2+ and ATP binds through the 
hydrogen bonds that formed between the adenine ring and the kinase ‘hinge’ — a 
segment that connects the amino- and carboxy-terminal kinase domains (Johnson et al., 
1998).  
In general, kinase inhibitors are commonly designed to block the phosphorylation 
activity of a specific kinase and in turn interfere with the signaling pathway(s) that it 
regulates. As a result of the great needs to explore new drugs to treat the kinase-related 
cancers or inflammatory diseases, an increasing number of kinase inhibitors have been 
discovered in the past decades. Most existing kinase inhibitors could be divided into 
three types, with most of them belong to the type-I ATP-competitive compounds (Zhang 
et al., 2009). 
Type I kinase inhibitors are small molecules that bind to the ATP-binding cleft of 
kinases in their active conformations and comprise the bulk of ATP-competitive 
inhibitors (Liu and Gray, 2006). These inhibitors typically consist of heterocyclic ring 
systems that bind in and around the purine-binding sites, which are occupied by the 
adenine ring of ATP when the kinases are in their active conformations. Since SRPK1 
adopts a constitutively active conformation at all time, SRPIN340 described above thus 
belongs to this type of inhibitors. The major advantage of type 1 inhibitors is that they 
are easy to characterize and be synthesized to mimic ATP. However, all Type I 
inhibitors bind to the conserved ATP binding sites of active kinases, so they suffer from 
widespread cross-reactivity among other kinases due to lack of specificity. The 
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nonspecific problem leads to serious side effect and poor safety in real medicinal 
treatment.  
 Type II kinase inhibitors bind to the same area occupied by the Type I compounds 
but recognize the binding pocket in special conformations that exist only when the 
kinases are inactive. In particular, when a kinase becomes inactivated, the DFG motif, 
which is responsible for anchoring the activation loop of a kinase in its active 
conformation when the kinase is activated, adopt an “out” conformation that exposes an 
additional hydrophobic binding site directly adjacent to the ATP binding site. Structural 
comparison of different inactive kinases has unveiled that the conformations of their 
corresponding hydrophobic sites are mostly unique. These hydrophobic sites thus 
provide additional structural scaffolds for inhibitor interaction and serve as new basis 
for the design of more specific inhibitors. Several successful Type II kinase inhibitors 
such as imatinib, nilotinib (Manley et al., 2005) and sorafenib, are highly specific for 
their targeted kinases and have been widely used for treatment of different diseases. 
Therefore, due to the significantly higher specificity, type II inhibitors usually have 
better safety profiles as well as exerting fewer side effects unlike the type I inhibitors. 
However, since detailed structural information in a kinase in its inactive form is 
required to design a type II inhibitor, the discovery and development of this class of 
inhibitors is more difficult and need much longer process. 
Allosteric inhibitors make up the third type of kinase inhibitors, which binds an 
allosteric site outside the ATP-binding site (Ohren et al., 2004). Binding of an inhibitor 
at an allosteric site could lead to a change in the conformation of the kinase active site, 
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and consequently blocks kinase activity. When allosteric inhibition happens, the 
substrate can no longer fit the binding region owing to the changed shape of the kinase 
active site. Thus it is well accepted that allosteric inhibitors possess the highest 
specificity among the three classes of inhibitor that have been discussed so far，because 
each inhibitor would perform unique inhibition mechanism towards a particular kinase. 
CI-1040 is one of the well-known allosteric kinase inhibitor, which inhibits the activity 
of MeK1 and MeK2 by occupying a pocket adjacent to the ATP binding site. However, 
the development of type III kinase inhibitors suffer from a major downside, which is the 
kinase of interest must possess an allosteric site, and its detailed structural information 
on the site is necessary. 
Due to various problems of kinase inhibitors described above, more and more 
novel inhibitor design methods are being explored. It is well known that the 
protein-protein interactions are the basic regulation of life, including signal transduction 
and large molecular machines. Improper protein-protein interactions could affect many 
cell processes including activation or inhibition of downstream steps of metabolic or 
signaling pathways. Therefore design of therapeutics inhibitors for specific 
protein-protein interactions is an attractive approach because these inhibitors could 
provide new means to control or modify the pathway of interest (Zhong et al., 2007). 
Several successes in the development of inhibitors targeting protein-protein interaction 
sites including those on BCL-2 (Oltersdorf et al., 2005), S100B (Fry and Vassilev, 
2005), p56lck (Huang et al., 2004) and ERK2 (Hancock et al., 2005) have proven that it 
is indeed feasible to search for novel drugs against these interactions. One good 
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example that shows this approach could also be applied to kinase inhibitor development 
is provided by Shapiro group, who successfully used in silico method to identify a small 
molecule inhibitor of ERK2 by targeting a unique docking domain, which in turn 
disrupts interactions between ERK2 and its substrates (Hancock et al., 2005).  
 
1.12 Focus of study 
It has previously been shown that the interference of the interaction between 
SRPK1 docking groove and ASF/SF2 results in aberrant phosphorylation and subcelluar 
localization of ASF/SF2. Therefore, we propose to screen for inhibitors that bind to the 
docking groove of SRPK1, which might block the interaction between SRPK1 and 
ASF/SF2 and in turn interfere the phosphorylation event, resulting in the inhibition of 
ASF/SF2 activity during splicing of HIV-1 mRNA. 
Our aim is to use the AutoDock suite to perform structure-based virtual screening 
method to identify potential inhibitors that block the interaction between SRPK1 and 
ASF/SF2. Also we wished to evaluate the effects of the selected compounds on the 
splicing of HIV-1 mRNA, and subsequently viral infection and replication. 
Since such inhibitors do not inhibit the kinase activity of SRPK1, they should have 
minimal impact on its function during the regulation of splicing of endogenous genes 
and thus prevent deleterious side effects. Our work will provide the platform for future 










Chapter : Materials and MethodsⅡ  
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2.1 Materials 
2.1.1 Bacterial strain 
Escherichia coli (E. coli) strain DH5α was used for plasmid DNA amplication. E. coli 
strain BL21(DE3) pLysS was used for the expression of protein. 
2.1.2 Antibodies 
Mouse myc-tag primary antibody (Cell Signaling) was used for detecting the 
localization of ASF/SF2 with a concentration of 1:1000 in immunocytochemistry study. 
AlexaFlour ® 488 anti-mouse secondary antibody (Invitrogen) in a dilution of 1:1000 
was used for visualization. 
2.1.3 Cell line 
Human cervical adenocarcinoma epithelial cell line HeLa was used in this study. Cells 
were routinely cultured in Dulbecco's modified Eagle's medium (Invitrogen) 
supplemented with 10 % fetal bovine serum (Invitrogen). 
2.1.4 Plasmid 
SRPK1and SRPK1ΔNS3: Expression plasmids of His-tagged SRPK1 in pRSET vector, 
Sumo-His-SRPK1 in pET28a(+) vector and His-SRPK1ΔNS3 in pET15bvector was 
provided by Prof. C.K. Ngo of School of life sciences, Chinese University of Hong 
Kong.  
Expression plasmid of SRPK in PCMV-tag2 vector was provided by Dr. Mars Tao of 
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School of life sciences, Chinese University of Hong Kong.  
 
ASF/SF2: His-tagged ASF/SF2 in pET15b vector and GST-tagged ASF/SF2 in 
pGEX4T2 vectorwas provided by Prof. C.K. Ngo. 
pCMV-myc-tagged ASF/SF2 was generated by PCR reaction using pET15b-ASF/SF2 
as template,  
The N-terminal primer containing an EcoR1 restriction site:  
AAGAATTCGGATGTCGGGAGGTGGTGTG 
The C-terminal primer containing an Xho1 restriction site: 
GTTTCTCGAGTTATGTACGAGAGCGAG 
After amplification, the PCR reaction products was first double digested with the 
restriction enzymes, gel purified and inserted into the mammalian expression vector 
PCMV-Myc, provided by Dr. Mars Tao of School of life sciences, Chinese University of 
Hong Kong.  
 
pΔPSP: used for the transfection and ex vivo splicing assay is a gift from the University 
of Lowa. 
The plasmid was a construct of HIV-1 plasmid deleted between nt 1511 and 4551. To 
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generate the pΔPSP, infectious HIV-1 plasmid pNL4-3 (GenBankTM accession  
number: M19921) was cleaved with SpeI and BalI nucleases to generate an 11.9-kb 
fragment. Then the fragment was ligated together with oligonucleotides 
5′-CTAGACGCGTTTGG-3′ and 5′-CCAAACGCGT-3′, which had been previously 
annealed, to form a double-stranded linker.  
2.1.5 Reagents 
Reagents are shown in Table 2.1. 
 
2.2 Expression and purification of Recombinant protein 
His-SRPK1ΔNS3: E.coliBL21(DE3) pLysS cells were transformed with 
pET15b-SRPK1ΔNS3. Large scale culture were grown in 4L of LB with 200 μg/ml 
ampicillin to O.D.600 0.6 at 37℃ and induced with 0.1 mM IPTG, the shaking 
overnight at 16℃. After centrifuged at 8000 rpm, the cell pellet were resuspended in 
120 ml of lysis buffer containing 20 mM MES pH 6.5, 250 mM NaCl, 10% glycerol, 1 
mM PMSF. The resuspended cells were lysed by sonication on ice. The solution was 
centrifuged and the supernatant were loaded onto a fast Q-sepharose column. The 
column was washed with 40 ml lysis buffer. The flow through sample was combined 
with the wash and the concentration of NaCl was brought up to 250 mM. The mixture 
was loaded on to a Ni2+ affinity column equilibrated with 40 ml of buffer containing 20 
mM MES pH 6.5, 250 mM NaCl, 10% glycerol and 5 mM imidazole, followed by 40  
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 Table 2. 1 List of solutions and commercial products used in this study 
Solutions Composition 
Molecular cloning 
Luria-Bertani (LB)  
medium and broth 
Commercial product from USB Affymetrix 
TAE buffer 40 mM Tris-acetate ( pH 8.0 ), 1 mM EDTA 
Agarose gel loading dye 0.25 % Bromophenol blue, 0.25 % Xylene Cyanol FF, 25 % Ficoll 400, 
0.1 % SDS 
Miniprep kit Commercial product from Intron 
Gel extraction kit Commercial product from Intron 
Tissue culture 
Phosphate Buffer Saline 
( PBS ) 
Commercial product from Sigma-Aldrich  
Dulbecco’s modified 
Eagle’s medium 
Commercial product from Invitrogen 
Fetal Bovine Serum Commercial product from Invitrogen 
LipofectamineTM 2000 
transfection reagent  
Commercial product from Invitrogen 
 
Protein expression and analysis 
Acrylamide / Bis solution 40 % Acrylamide  / Bis ( 37.5:1 ) from Bio-Rad 
Stacking buffer 0.5 M Tris-HCl ( pH 6.8 ) 
Stacking arcylamide gel 
(18x16mm) 
2.2ml distilled H2O, 0.38 ml 40 % acrylamide / bisacrylamide 
( 37.5:1 ), 0.38 ml Resolving buffer, 30 μl 10% SDS, 30 μl of 
20% ammonium persulphate (APS, Sigma-Aldrich) and 3 μl 
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N,N,N,N,-Tetramethylethylendiamin (TEMED, Invitrogen). 
Resolving buffer 1.5 M Tris-HCl ( pH 8.8 ) 
12.5 % Resolving arcylamide gel 
(18x16mm) 
2 ml distilled H2O, 1.56 ml 40 % acrylamide / bisacrylamide 
( 37.5:1 ), 1.3 ml Resolving buffer, 50 μl 10% SDS, 50 μl of 
20% APS and 5 μl TEMED 
SDS-PAGE buffer 25 mM Tris-HCl ( pH 8.3 ), 250 mM Glycine, 0.1 % SDS 
Transfer buffer 25 mM Tris-HCl, 192 mM Glycine, 20 % Methanol 
1 X TBS 20 mM Tris, 137 mM NaCl, pH 7.6 
1 X TBST TBS ( pH 7.6 ), 0.1 % ( v / v ) Tween 20  
Blocking solution for western blot 5 % (w / v) Non-fat dried milk in TBST 
Stripping buffer 62.5 mM Tris, 2 % SDS,  0.1 M -mercaptoethanol, pH 6.7 
Bio-Rad Protein Assay Reagent Commercial product from Bio-Rad 
BenchMarkTM Prestained Protein 
Ladder 
Commercial product from Invitrogen 
Immunocytochemistry 
4 % PFA 4 % paraformaldehyde in PBS 
4, 6-diamidino-2-phenylindole ( DAPI ) 2 μg / ml DAPI in PBS 
Fluorescent Mounting Medium  Commercial product from Dako Cytomation 
RT-PCR 
Trizol® Reagent Commercial product from Invitrogen 
MLV-RT Commercial product from Genesys 
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 ml of wash buffer with 40 mM imidazole. Then the protein was eluted with 30 ml of 
buffer containing 200 mM imidazole. The elution was dialysed overnight in 1L of buffer 
consisted of 20 mM MES pH 6.5, 250 mM NaCl, 10% glycerol to remove the imidazole. 
His-tag protein was then cleaved with thrombin and concentrated to less than 2 ml. 
Protein was loaded onto a Sueprdex 200 size exclusion column equilibrated with 20 
mM MES pH 6.5, 250 mM NaCl, 10% glycerol and 1 mM DTT. The pooled peak 
fractions were concentrated to ~6 mg, aliquoted and stored in -80 ℃. 
 
Sumo-His-SRPK1:E.coliBL21(DE3) pLysS cells were transformed with 
pET28a(+)-SRPK1. Large scale culture were grown in 4L of LB with 100 μg/ml 
kanamycin to O.D.600 0.6 at 37℃ and induced with 0.1 mM IPTG, the shaking 
overnight at 16℃. After centrifuged at 8000 rpm, the cell pellet were resuspended in 
120 ml of lysis buffer containing 20 mM MES pH 6.5, 300 mM NaCl, 10% glycerol, 3 
mM PMSF. The resuspended cells were lysed by sonication on ice. The solution was 
centrifuged and the supernatant were loaded onto a fast Q-sepharose column. The 
column was washed with 40 ml lysis buffer. The flow through sample was combined 
with the wash and the concentration of NaCl was brought up to 300 mM. The mixture 
was loaded on to a Ni2+ affinity column washed with 40 ml of buffer containing 20 mM 
MES pH 6.5, 300 mM NaCl, 10% glycerol and 5 mM imidazole, followed by 40 ml of 
wash buffer with 40 mM imidazole. Then the protein is eluted with 30 ml of buffer 
containing 200 mM imidazole. The elution was dialysed overnight in 1L of buffer 
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consisted of 20 mM MES pH 6.5, 300 mM NaCl, 10% glycerol to remove the imidazole. 
Sumo-His-tag protein was then cleaved with SENP1C and then loaded onto the 
GST-column combined with Ni2+ affinity column to remove the sumo-his tag. The 
column was washed with buffer containing 20 mM MES pH 6.5, 300 mM NaCl, 10% 
glycerol. The GST-column was moved away and the Ni2+ affinity column was eluted 
with buffer (20mM MES pH 6.5, 300 mM NaCl, 10% glycerol and 30 mM imidazole). 
The eluted protein was concentrated to less than 2 ml. Protein was loaded onto a 
Superdex 200 size exclusion column equilibrated with 20 mM MES pH 6.5, 250 mM 
NaCl, 10% glycerol and 1 mM DTT. The peak eluted fractions were combined, 
concentrated to ~4 mg, aliquoted and flash frozen, and stored in -80 ℃. 
 
His-SRPK1:E.coliBL21(DE3) pLysS cells were transformed with in pRSET-SRPK1. 
Large scale culture were grown in 4L of LB with 100 μg/ml kanamycin to O.D.600 0.6 
at 37℃ and induced with 0.1 mM IPTG, the shaking overnight at 16℃. After 
centrifuged at 8000 rpm, the cell pellet were resuspended in 120 ml of lysis buffer 
containing 20 mM MES pH 6.5, 300 mM NaCl, 10% glycerol, 3 mM PMSF. The 
resuspended cells were lysed by sonication on ice. The solution was centrifuged and the 
supernatant were loaded onto a fast Q-sepharose column. The column was washing with 
40 ml lysis buffer. The flow through sample was combined with the wash and the 
concentration of NaCl was brought up to 300 mM. The mixture was loaded on to a Ni2+ 
affinity column washed with 40 ml of buffer containing 20 mM MES pH 6.5, 300 mM 
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NaCl, 10% glycerol and 5 mM imidazole, followed by 40 ml of wash buffer with 40 
mM imidazole. Then the protein was eluted with 30 ml of buffer containing 200 mM 
imidazole. The elution was dialysed overnight in 1L of buffer consisted of 20 mM MES 
pH 6.5, 300 mM NaCl, 10% glycerol to remove the imidazole. The eluted protein was 
concentrated to less than 2 ml. Protein was loaded onto a Sueprdex 200 size exclusion 
column equilibrated with 20 mM MES pH 6.5, 250 mM NaCl, 10% glycerol and 1 mM 
DTT. The peak eluted fractions were combined, concentrated to ~4 mg, aliquoted and 
flash frozen, and stored in -80 ℃. 
 
GST-ASF/SF2: E.coliBL21(DE3) pLysS cells were transformed with 
pGEX4T2-ASF/SF2. Large scale culture were grown in 2L of LB with 200 μg/ml 
ampicillin to O.D.600 0.6 at 37℃ and induced with 0.1 mM IPTG, the shaking 
overnight at 25℃. After centrifuged at 8000 rpm, the cell pellet were resuspended in 
120 ml of lysis buffer containing 20 mM Tris pH 7.5, 50 mM NaCl, 10% glycerol, 1 
mM PMSF and 1 mM DTT. The resuspended cells were lysed by sonication on ice and 
centrifuged to remove insoluble fraction. The supernatant were loaded onto a fast 
Q-sepharose column. The column was washed with 40 ml lysis buffer. The flow through 
and wash from the Q-sepharose column were combined and loaded onto the 
GST-column overnight at 4℃. GST-column was wash with 20 ml of buffer contain 20 
mM Tris pH 7.5, 500 mM NaCl, 10% glycerol and 1 mM DTT and eluted with buffer 
containing 100 mM glutathione. The elution was dialysed overnight in 1L of buffer 
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consisted of 20 mM Tris pH 7.5, 500 mM NaCl, 10% glycerol and 1 mM DTT. Finally, 
the protein was concentrated to ~2 mg, aliquoted and flash frozen, and stored in -80 ℃. 
 
His- ASF/SF2: E.coliBL21(DE3) pLysS cells were transformed with pET15b-ASF/SF2. 
Large scale culture were grown in 200 ml of LB with 200 μg/ml ampicillin to O.D.600 
0.6 at 37℃ and induced with 0.1 mM IPTG, the shaking overnight at 25℃. Cells were 
then pelleted and lysed by sonication on ice using 20 ml of lysis buffer (0.1 m MOPS, 
10 mm Tris-HCl, pH 8.0, 300 mm NaCl, 10% glycerol, 1 mm PMSF). The insoluble 
fraction was collected by centrifugation at 20,000 rpm for 30 min, washed twice with 
lysis buffer containing 2 M urea, and then resuspended in denaturing buffer (lysis buffer 
containing 8 m urea) overnight at room temperature. The soluble fraction, collected by 
centrifugation at 20,000 rpm for 30 min, was loaded onto a Ni2+ affinity column and 
washed with denaturing buffer containing 20 mm imidazole. The protein was re-folded 
by passing decreasing concentrations of urea through the column (8, 6, 4, 3, 2, 1, and 0 
M urea). The re-folded protein was eluted with 20 ml of elution buffer (0.1 m MOPS, 10 
mm Tris-HCl, 0.3 m NaCl, and 10% glycerol, pH 3.0). The pH of the eluted protein was 
changed to 7.0 by using NaOH. Protein was aliquoted and flash frozen, and stored in 
-80 ℃. 
 
2.3 In silico screening of inhibitors 
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The program AutoDock Vina and AutoDock 4.2 were used to screen a virtual library of 
approximately 500,000 low molecular weight compounds collected from natural 
compound database and SPECS from ZINC. Database screening targeted a region of the 
docking groove on SRPK1 occupied by the RS-domain of ASF/SF2.  
 
2.4 Kinase Glo Assay 
Equilibrate the Kinase GLO assay buffer to room temperature before use. 5 nM SRPK1 
wild type protein and 500 nM His-ASF/SF2 were incubated in the 384-well plates with 
different inhibitors or DMSO in 50 mM Tris-HCl pH 7.5, 10 mM MgCl2 and 5 mg/ml 
BSA at 22 ℃. To all wells, the reaction was initiated by adding cold ATP and then 
reactions were quenched by addition of equal amount Kinase GLO assay buffer. The 
plate is shaked and incubated for 10 minutes at room temperature. Finally, luminescence 
was recorded. 
 
2.5 In vitro kinase assay 
Five nanomoles SRPK1 wild type protein and 500 nM His-ASF/SF2 were incubated in 
the presence of 32P-ATP and different concentration of inhibitors or DMSO in 50 mM 
Tris-HCl pH 7.5, 10 mM MgCl2 and 5 mg/ml BSA at 22 ℃. Then reactions were 
quenched by addition of 4X SDS buffer and subsequent boiling. Reaction mixes were 
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run on a 12.5% SDS gel. The gel was dried and exposed to autoradiography film. The 
bands’ intensity were quantitated using a Phosphorlmager and the ImageQuant software 
(GE Healthcare). The result will be plotted against the inhibitor concentration added to 
the kinase reaction. The value of IC50 for each inhibitor was determined from these 
data by non-linear least squares regression analysis. 
 
2. 6 Cell Culture 
HeLa ( ATCC cat. No. CRL-2 ) was routinely cultured in Dulbecco’s modified Eagle’s 
medium (Invitrogen) with 10% Fetal Bovine Serum (Invitrogen) at 37°C incubator 
supplied with 5 % CO2. Cell passage was performed in 1 to 8 ratio by trypsination. 
 
2. 7 MTT Assay 
The MTT assay (Roche) was conducted according to manufacturers’ instruction. Ten 
thousands Hela cells were cultured on each 96-well and was incubated for 6 hours. 
Drugs or DMSO were added directly to each well. Cells were treated with drugs for 24h 
in triplicate. Ten microliters of MTT Reagent 1 was added to each well and incubated 
for 4 hours until purple precipitate is visible at 37°C. A hundred microliters of detergent 
reagent was then added and left in 37°C incubator overnight. Finally, the absorbances 
were measured by spectrometer (Molecular Devices) at 580 nm, with 680 nm as 
reference. 
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 2. 8 Immunocytochemistry 
HeLa cells were cultured on glass coverslips 12 hours before transfection. Drugs were 
treated 4h after tansfection. The coverslips with cells were collected 4 hours after 
drug-treatment and were fixed with 4 % paraformaldehyde (PFA) in PBS for 20 minutes. 
The coverslips were then washed with PBS for 3 times and blocked with 10 % normal 
donkey serum (Sigma-Aldrich) at room temperature for 1 hour. The cells on the 
coverslips were then incubated with primary antibody in PBS with 5 % donkey serum 
and 0.3% Triton-X at 4 °C overnight. All the washings were performed by PBS 
supplemented with 0.3% Triton-X later on. After washing for 3 times, cells were then 
incubated with corresponding AlexaFluor® secondary antibodies for one hour at room 
temperature. Finally cells were washed three times, counterstained with 2 μg / ml 4, 
6-diamidino-2-phenylindole (Roche) for 5 minutes, washed again with PBS, mounted 
on glass slides using fluorescent-mounting medium (Dako Cytochromation) and sealed 
with nail enamel. Immunoflorescence were visualized under epifluorescence 
microscope (Olympus) and images for the same antigen were captured using the same 
laser settings. 
 
2.9 Ex vivo splicing assay 
Hela cells or HEK293 cells were grown in DMEM, supplemented with 10% FBS on 
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6-well plate. After 24 h, each well was co-transfected with splicing reporter constructs 
pΔPSP and EGFP plasmid with Lipofectamine (Invitrogen) according to the 
manufacturer's instructions. Four hours later, the chemicals to be tested were added in 
culture media. The chemicals were added from DMSO stocks (final DMSO 
concentration in the media 1%).  
Total cellular RNA was isolated from transfected HeLa cells 48 h post-transfection 
using Trizol Reagent (Invitrogen), and 3 μg of RNA was reversed transcribed with 
random hexamers using MLV-RT (Genesys Ltd) in standard 37℃ protocol. PCR 
amplified with forward primer BSS (5′-GGCTTGCTGAAGCGCGCACGGCAAGA 
GG-3′; nt 700–727) and reverse primer SJ4.7A, which spans sites D4 and A7 
(5′-TTGGGAGGTGGGTTGCTTTGATAGAG-3′; nt 8369–8381 and 6032–6044), 
following an incubation of 1.5 min at 95℃, and 24 cycles of 1 min at 95℃, 30 s at 59℃, 
and 30 s at 72℃, the reaction was ended with an extension step of 10 min at 72℃. To 
normalize the signals, GAPDH was used as an internal control of the PCR reactions as 
described. Amplified spliced products are confirmed by 10% polyacrylamide gel 
electrophoresis (PAGE). 
 
2.10 Surface plasmon resonance spectroscope 
GST antibody was immobilized on all flow cells of the Biacore CM5 sensor chip. 
Recombinant GST-ASF/SF2 protein was immobilized on a Biacore CM5 Chip with 
GST antibody. The final response obtained was 700 RU (response units) (1 response 
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unit corresponds to 1 pg of protein per mm2) of immobilized GST-ASF/SF2. Purified 
SRPK1 was maintained at 50 nM in running buffer (10 mM HEPES, 0.15 M NaCl, pH 
7.4). SRPK1 was preincubated with the test compounds at varying concentrations, and 











Chapter Ⅲ: Results 
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3.1 In silico screening of inhibitors 
The structure of SRPK1 (PDB ID: 1WAK) is selected for the docking experiment 
and 351,473 compounds from the natural products database of ZINC 
(http://zinc.docking.org/) and the commercially available SPECS synthetic compound 
library were used for screening. Natural products offer diverse chemical and structural 
complexity, and unmatched biological potency. It is not unusual that a natural product 
‘hit’ from screening can become a drug directly. Therefore, we performed in silico 
screening using a natural compound database which contains nearly 90,000 compounds 
that are either pure natural products or simple chemical derivatives of natural products. 
Compounds included in the database are commercially available from 7 vendors, so 
compounds identified as potential hits could be easily purchased for further analysis. In 
addition, we have also chosen the database of SPECS compounds that are highly 
affordable and exhibit structural characteristics of biologically active compounds, and 
meet Absorption Distribution Metabolism Excretion (ADME) requirements. 
Structural analyses of the SRPK1-peptide and the SRPK1-ASF/SF2 complexes 
both indicate that the docking groove of SRPK1 interacts with the binding partners with 
near perfect shape and charge complementarily. Furthermore, previous studies have 
confirmed that 4 residues (D548, D564, E571, and K615) within the docking groove are 
critical for the stability of the complexes as well as the mechanism of phosphorylation 
of ASF/SF2. Therefore, the docking groove was selected for in silico screening to 
identify low-molecular-weight compounds with the potential to bind to this site and 
subsequently block binding and phosphorylation of ASF/SF2. Inhibition of ASF/SF2 
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phosphorylation might in turn abrogate its function during HIV-1 splicing and prevent 
HIV-1 virus from completing its life cycle.  
 To prepare for the screening, the SRPK1 structure (PDB ID: 1WAK) was 
edited using the software provided by the ADT package of the AutoDock Suite to fix 
problems like missing atoms, added waters, and alternate locations. Polar hydrogen 
atoms were also added to the macromolecule and Gasteiger charges were calculated for 
all atom types present in the screening library. Three-dimensional affinity grid (Figure 
3.1) that is used to specify the site of interest for inhibitor screening was positioned 
around the docking groove and calculated for all atom types present in the screening 
library. This defined potential grid was then used to dock all compounds in the selected 
libraries. 
Next, the small molecule compound candidates were first filtered using criteria set 
out by the Lipinski’s Rule of Five: MW<500, hydrophobicity (Log P) between -4 and 4, 
number of hydrogen bond donor <5, and acceptor <10. This selection ensures the 
compounds identified by the docking programs as hits would be suitable for used in 
experimental testing and have the potential to be developed into drugs (Figure 3.2). 
Compounds that did not fit any of the criteria were discarded and those that passed the 
filtering were converted to AutoDock format for the docking experiment. 
To improve the confidence of the docking results in our experiment, we performed 
two rounds of docking using two different programs AutoDock Vina and AutoDock 4.2. 
First, we took advantage of the high docking efficiency of AutoDock Vina to screen 
351,473 compounds in our selected natural products and SPECS libraries. Then,  
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 Figure 3. 1 Docking grid set on the docking groove of SRPK1 for in silico screening. 
The docking groove of SRPK1, which is necessary for the substrate binding, is located 
at the large lobe and is covered in the drawn docking grid. The area covered by the 





Figure 3. 2 Examples of small molecules from the natural products and SPECS libraries. 
The libraries were filtered by the Lipinski’s Rule of Five criteria - MW<500, 
hydrophobicity (Log P) between -4 and 4.2, number of hydrogen bond doner <5, and 
acceptor <10, before being submitted to the docking program.
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potential hits obtained from AutoDock Vina were subjected to a second round of 
docking in AutoDock 4.2, and only those compounds that are also identified by 
AutoDock 4.2 as hits were further analyzed and selected for experimental testing. Since 
the algorithms used for the docking and scoring are completely different in the two 
programs, this two-steps docking procedure would serve as a non-bias double-checking 
system for potential hits being identified. Compounds that survived both screenings 
should have higher potential to be true binders to SRPK1 when compare to using a 
single program alone.   
During the first round of screening, compounds were selected if they met the 
following requirements: 1) the binding free energy is among the lowest 1% among all 
screened compounds; 2) must be lower than -8 kcal/mol; 3) the RMSDs between 
different docking models of the same compound are lower than 4 Å. These 
requirements were set to ensure that the selected compounds bind to the binding pocket 
stably and tightly. 
In the second round of docking, 2846 compounds selected from the first screening 
by AutoDock Vina were inputted into the AutoDock 4.2 program. Lamarckian genetic 
algorithm (LGA) was employed to search for ligand conformations using docking 
parameters as follow: population size of 120 individuals, maximum numbers of 
generations and energy evaluations of 27000 and 1.7 million respectively, 50 docking 
runs, and random initial positions and conformations AutoDock 4.2 has a free-energy 
scoring function that uses the AMBER force field to estimate the free energy of binding 
of a ligand to its target. The binding free energies of different runs of each compound 
 55
were examined by clustering with an RMSD tolerance of 0.7Å.The docking results of 
target compounds were ranked in a list on the basis of the mean estimated binding free 
energies of their most populated clusters. The compounds with the lowest binding free 
energies were ranked at the top of the list. Since there was no known inhibitor for the 
target site can be used for control docking, no free energy cutoff was present and we 
simply selected the top 1-2% of ranked compounds after each screening round. The top 
ranking ligands were then selected for inspection visually and evaluated based on their 
interactions with the kinase docking groove. The whole screening procedures are 
showed in Figure 3.3 and the docking results of the selected compounds are listed in 
Table 3.1. 
Nearly all screened inhibitors were predicted to bind in the vicinity of the targeted 
binding site and adopted a variety of orientations within the SRPK1 docking groove. 
After inspecting their interactions within the docking groove, 42 compounds including 8 
from the Natural Product library and 34 from the SPECS synthetic library that interact 
with the kinase reasonably and favorably were selected for further biochemical analysis 
(compounds selected from SPECS library will be labeled with a numerical symbol 
based on the order they were identified; compounds identified from the Natural Product 
database will be designated starting with the letter N, followed by a numerical symbol, 
e.g. N-1, N-2, etc. from now on). Docking results of the selected compounds are listed 
in Table 3.1 and figure 3.4 illustrate examples of selected compounds docked to the 






Figure 3. 3 Flow chart of the in silico drug screening. Small compound candidates were 
first filtered by the Lipinski’s Rule of Five criteria, following by the two rounds of 




Figure 3. 4 Examples of predicted binding of active compounds to SRPK1. The binding 
modes of two compounds at the docking groove of SRPK1 are shown. SRPK1structure 
is shown in surface rendition and colored. The chemical structure of the compounds 




3.2 Selected Compounds Inhibits SRPK1 in Vitro 
3.2.1. Protein purification 
A. SRPK1 purification 
We first expressed and purified both recombinant SRPK1 and ASF/SF2 so we 
could perform in vitro assays to test the effects of different inhibitors identified in our in 
silico screening. For the expression of SRPK1, I have subcloned it into the 
SUMO-pET28a(+) expressing vector. This vector was provided by Prof. Shannon Au’s 
group at the School of Life Sciences at CUHK. It was modified from pET28a vector by 
inserting the sequence of SUMO protein between the poly-histidine tag and the coding 
region. Sumo-pET28a(+)-SRPK1 were transformed into BL21(DE3) plysS cells and 
used to express recombinant protein under the induction of IPTG. 
Protein sample was loaded on an anion exchange chromatographic column 
(Q-column) that is connected directly to a cation exchange chromatographic column 
(S-column) at a NaCl concentration of 50 mM and pH 6.5.After washing, the proteins 
remained on the S column was eluted using a concentration gradient of NaCl. SRPK1 
was eluted at around 400 mM salt concentration (Figure 3.5). 
After the first step of purification by tandem anion-cation exchange 
chromatography, SRPK1 was then applied to Ni2+-NTA column (Figure 3.5) in the 
presence of 5 mM imidazole, which was expected to effectively block most non-specific 
binding. The loaded column was then washed by buffer containing 50 mM imidazole 
and the protein was finally eluted with eluting buffer that contains 200 mM imidazole. 
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 Figure 3. 5 Q & S ion-exchange chromatography and Ni2+-NTA affinity 
chromatography purification of wild type SRPK1. A) 12.5% SDS gel analysis of 
SRPK1 wild type purified by Q & S columns. The flow-through fraction from the 
Q-sepharose column was loaded directly onto the S-sepharose column followed by the 
gradient elution of NaCl. The gel showed that elution 22-34 contained SRPK1 wt. B) 
12.5% SDS gel analysis of SRPK1 wild type purified by Ni2+-NTA Column. Loaded 
sample was collected from the elution fractions 20 to 37 from Q & S column 
purification. SRPK1 was eluted efficiently at 200 mM imidazole buffer. 
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 Figure 3. 6 Gel filtration chromatography purification for SRPK1. A) UV curve of 
elution profile. B) SDS-PAGE of the eluted fractions after gel filtration chromatography. 
Samples 33 to 36 were collected for concentration. 
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 Figure 3. 7 SRPK1 wild type is monodisperse at pH 6.5. Dynamic light scattering (DLS) 
experiment was performed to analyze the protein. Protein was dialysed against different 
buffers with different pH. A) MES pH 6.5, B) MES pH 6.0, C) Tris pH 7.0 D) Tris pH 
8.0 E) CAPSO pH 9.0. The results from DLS experiment suggested that MES pH 6.5 is 
the optimal buffer to be used during the purification process.  
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SRPK1 was eluted in elution fractions 1-3. SDS-PAGE analysis of the elution from 
Ni2+-NTA column, however, showed that the purity of SRPK1wt protein has improved 
only slightly after this step. Next, I cleaved off the His-SUMO tag using purified 
SUMO protease SENP1C and reloaded the cleavage product on the Ni2+ column again 
to remove the cleaved tag. Finally, gel filtration was performed to further purified the 
protein. Proteins eluted from the gel filtration column were analyzed by SDS-PAGE 
again and flash frozen for storage. Figure 3.6 shows the final level of purity of SRPK1 
wt. 
A dynamic light scattering (DLS) experiment was performed to analyze if the 
purified protein is homogeneous by dialyzing it against buffers with different pH. 
Compared with the other 4 conditions, the width of the peak in condition containing 
MES pH 6.5 represented less broadness of the size distribution and indicated more 
monomodal distribution of protein particle sizes, suggesting the protein is monodisperse 
at this pH. These results confirmed that MES pH 6.5 is the optimal buffer to be used 
during the purification process (Figure 3.7).  
 
B. ASF/SF2 purification 
ASF/SF2 was subcloned into the pET15b vector with poly-histidine. E.coli 
BL21(DE3) pLysS cells were transformed with pET15b-ASF/SF2 and induced with 
IPTG. Cells were then pelleted and lysed by sonication and the soluble and insoluble 
fractions were separated by centrifugation. Recombinant His-ASF/SF2 expressed in E. 
coli as inclusion bodies. Therefore, we purified the protein under denaturing condition  
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Figure 3. 8 Refolding and purification of (His)6-tagged ASF/SF2 wild type. Denatured 
soluble fraction was load onto a Ni2+ affinity column and washed with denaturing buffer. 
The protein was refolded on column by passing decreasing concentrations of urea. The 
refolded protein was eluted with low pH elution buffer.  
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and performed refolding to obtain soluble His-ASF/SF2 protein. First, the collected 
insoluble fraction was first denatured using urea. Next, the denatured sample was 
loaded onto a Ni2+ affinity column and washed under denaturing condition. The protein 
was then refolded by passing decreasing concentration of urea through the column. The 
protein refolded on column was eluted using buffer at pH 2. The pH of the eluted 
protein was later adjusted to 7.0 by adding NaOH slowly (Figure 3.8). 
 
3.2.2 Inhibits ASF/SF2 Phosphorylation by SRPK 
A. Screening using Kinase-Glo assay 
To determine whether the 34 SPECS compounds selected by AutoDock Vina and 
AutoDock 4.2 could inhibit the phosphorylation of ASF/SF2, we first performed the 
kinase-glo assay for a fast screening. The assay was performed in a 96-well white plate. 
Each well contains His-ASF/SF2, SRPK1wt, ATP, MgCl2 and different concentrations 
of the selected compounds. The reactions were allowed to proceed for 5 mins and 
quenched by adding one volume of Kinase-Glo Reagent to the completed kinase 
reaction. ATP remaining at the time that the reagent was added was used as a substrate 
by the Ultra-Glo™ Luciferase to catalyze the mono-oxygenation of luciferin. 
Luminescence generated by luciferase reaction was measured using a luminometer. By 
comparing the luminescence of the reactions carried out in the presence of compounds 
and the vehicle control (dimethyl sulfoxide [DMSO]), the compound activity on SRPK1 
could be determined. 
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Despite the candidate compounds were filtered using the criteria set in the 
Linpinski’s Rule of Five, three compounds, N1, N3 and N6 from natural products 
library, and 5 compounds including compound 1, 3, 13, 17 and 19 from SPECS library 
remained insoluble in the presence of high concentration of DMSO.  
However, 34 compounds selected from screening were finally tested in the 
Kinase-Glo assay to determine their inhibitory activities on the phosphorylation of 
ASF/SF2 by SRPK1. 16 out of the 34 soluble compounds selected, including five 
compounds from natural product library and compound 23, 24, 25 and etc, did not 
produce consistent results using this method. Therefore, their activities were reassessed 
using radioactive phosphorylation assay. All compounds were tested two times using 
their highest soluble concentration, ranging from 1000μM to 25μM. Since some 
compounds produced inconsistent results in different trials of Kinase-Glo assays, I 
double checked the screening results by performing compounds that could not be 
determined by the Kinase-Glo assay. 
Four compounds out of 34 soluble compounds tested, including N7, compound 5, 
24 and 36 consistently attenuated SRPK1 phosphorylation activity compared with 
vehicle control (DMSO)(Figures 4.5). Structures and properties of the selected 
compounds are shown in the Table 3.2 and 3.3. Furthermore, since compound 5 showed 
strong inhibition on the phosphorylation of ASF/SF2 by SRPK1, I further identified 
three compounds that are structurally similar to the active compound 5, namely 
compound D1, D2 and D3, from the PubChem. They were purchased and subjected to 
the Kinase-Glo assay as well.   
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Figure 3. 9 In vitro kinase assays were performed to test the effect of compounds on the 
kinase activity of SRPK1.A) In vitro kinase Glo assays. The y axis shows the relative 
percent of phosphorylation of His-ASF/SF2 in the presence of selected compounds 
(black bars). Compounds tested but did not produce consistent data are excluded from 
this chart. B), C) and D): In vitro radioactive kinase assays to reassess some results from 
the Kinase-Glo assays as well as testing the inhibitory activities of natural compounds. 
Compound 5, D1, D2, D3, 24, 36 and N7 showed inhibition effect on the 
phosphorylation of His-ASF/SF2 by SRPK1. 
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While these structurally related compounds could also inhibit the phosphorylation 
of ASF/SF2 to some extent, compound 5 remained as the most potent inhibitor on the 
phosphorylation of ASF/SF2 (Figure 3.9).  
Some compounds shown lower inhibition even with the highest concentration were 
also been weeded out, like compound 24. All the left 6 compounds showed 
phosphorylation repression by greater than 50%, 6 from the SPECS and one from the 
Natural Compound database were all selected for next step study to get the IC50. 
 
 
B. In vitro radioactive Kinase assay to determine IC50 
Since only 5 out of the 8 compounds selected from the Natural Product library 
could be solubilized in 5% DMSO and subjected to kinase activity assays, they were 
directly tested using in vitro radioactive kinase assays instead of the quick Kinase-Glo 
screening method (Figure 3.9D). The reaction was initiated with 50 μM ATP and trace 
amounts of γ32P-ATP. The phosphorylation intensity of ASF/SF2 was quantitated using 
a phosphorImager and ImageQuant software (GE Healthcare). Only compounds N5 and 
N7 were shown to inhibit phosphorylation of ASF/SF2, with N7 exerted stronger 
inhibitory effect. 
To evaluate the IC50s of the compounds that showed inhibition activities, the 
phosphorylation content of ASF/SF2 were measured in the presence of different 
concentrations of inhibitors. The phosphorylation content of ASF/SF2 relative to the 
untreated control was plotted against the inhibitor concentrations being used in the 
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reaction. Six compounds were shown to inhibit ASF/SF2 phosphorylation by SRPK1 in 
a dose-dependent manner. (Figure 3.10 and Figure 3.11). In particular, compounds 5, D2 
and N7 blocked more than 80% of phosphorylation of ASF/SF2 at the highest 
concentration being tested. From the in vitro kinase activity assay results, compound 5 
is calculated to have an IC50 value of 20 μM, whereas two structurally related 
compounds, compounds D1 and D3, showed better inhibitory activities with an 
IC50 value of 14.37 μM and 12.49 μM respectively (Figure 3.10). Results of compound 
36 and natural compound N7 showed their IC50 are 7.398μM and 36.26 μM 
respectively (Figure 3.11). 
Since natural compound N7 exhibited good inhibitory activity against the 
phosphorylation of ASF/SF2 by SRPK1, we obtained five structurally related 
derivatives from our collaborator Prof. Jiang at the Macau University of Science and 
Technology. Two of these natural compounds, rhynchophylline and yohimbine 
hydrochloride (Table 3.4), however, showed no inhibitory activity against the 
phosphorylation of ASF/SF2 when used at the indicated dosage (Figure 3.12). 





Figure 3. 10 In vitro kinase assay for compound 5, D1, D2 and D3. SRPK1, 
His-ASF/SF2 and inhibitors were incubated in 1× kinase buffer (100 mM Tris-HCl [pH 
7.5], 10 mM MgCl2, 5mg/ml BSA, and 1 mM DTT). The reaction was initiated with 50 
uM ATP and trace amounts of γ32P-ATP. The gel was dried and the bands are 
quantitated using a Phosphorlmager and the ImageQuant software (GE Healthcare).  
The results are plotted against the inhibitor concentration added to the kinase reaction. 
























































Figure 3. 11 In vitro kinase assay for compound 36 and natural compound N7. 
Experiment conditions are the same as in Figure 3.10. Compound N7 inhibited nearly 
50% of ASF/SF2 phosphorylation even at the lowest concentration tested, while 
inhibited more than 90% of phosphorylation at 1 mM. 
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Figure 3. 12 In vitro kinase assay for rhynchophylline and yohimbine hydrochloride. 
Experiment conditions are the same as in Figure 3.10. The rhynchophylline and 
yohimbine hydrochloride failed to inhibit the phosphorylation of ASF/SF2. 
 
 75
3. 3 Surface Plasmon Resonance Binding Competition Assay 
To test if the compounds inhibited the phosphorylation event by blocking 
protein-protein interactions between SRPK1 and ASF/SF2, I used surface plasmon 
resonance to measure if the inhibitors could affect SRPK1-ASF/SF2 binding. GST-tag 
ASF/SF2 was immobilized on a CM5 sensor chip pre-coated with GST antibodies; 
SRPK1 protein was pre-incubated with different compounds or DMSO for 15 mins 
before being applied in the mobile phase. If the selected compounds inhibit the 
interaction between SRPK1 and ASF/SF2, they would prevent formation of complex on 
the sensor chip and thus result in lower SPR signal. During the experiment, compound 
23, which showed no inhibitory activity in our assays (Figure 3.13A), and a well known 
ATP-competing kinase inhibitor staurosporine were used as negative controls to show 
that the inhibition of interaction is specific and not due to binding of inhibitors at the 
ATP binding site. 
All compounds were tested twice in the assays using the highest concentration 
possible, which beyond that the compounds start to precipitate. While compound 5 
showed potent inhibitory effect in our phosphorylation assay, it did not appear to inhibit 
the interaction between SRPK1 and ASF/SF2 in the SPR experiment (Figure 3.13B). 
Instead, the SPR signal increased when the compound was applied in the mobile phase 
together with the kinase. An explanation to this observation is that the compound 
interacts with the protein complex at a site outside of the docking groove of SRPK1, 




















Figure 3. 13 Surface plasmon resonance sensorgrams for compound 5, D1, D2 and D3. 
Staurosporine and compound 23 were used as the negative control. The tested 





















































Figure 3. 14 Surface plasmon resonance sensorgram for natural compound N7. N7 
appears to inhibit the binding of SRPK1 to ASF/SF2 and the IC50 for binding inhibition 
was estimated to be around 250μM. 
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Compounds D1, D2 and D3that are structurally related to compound 5 lowered the SPR 
signal of the complex by 20-30% (Figure 3.13C). However, due to limited solubility, the 
compounds could not be tested using higher concentration and thus the dose-dependent 
effect and IC50s of these compounds could not be determined. 
Among all the compounds selected from the Natural Product library, compound N7 
is the most potent in inhibiting the phosphorylation of ASF/SF2. However, while 
compound N7 could lower SPR signal in a dose-dependent manner, the IC50 was 
estimated to be around 250 μM, which is much higher than that obtained from in vitro 
kinase assay (Figure 3.14). The reason for the difference is unknown and more 
experiments like GST-pull down assay are needed to directly test the effect of the 
compound on the interaction between SRPK1 and ASF/SF2. Nonetheless, the SPR 
result showed that compound N7 possesses the ability to inhibit the binding of ASF/SF2 
to SRPK1. 
 
3.4 Inhibitors Alters HIV-1 Alternative Splicing ex Vivo 
Given that ASF/SF2 plays a major role in HIV-1 pre-mRNA splicing, I tested the 
effects of 5 candidate compounds (natural compound N7, compound 5, D1, D2 and D3) 
on the HIV-1 pre-mRNA splicing using an ex vivo assay. pΔPSP plasmid, a HIV-1 
proviral genome with deletion between nucleotides 1511 and 4550 that remove the 
encoding gene of gag and pol, was used for the ex vivo splicing assay to evaluate the 
inhibition efficiency of each candidates. Pre-mRNA transcribed from pΔPSP plasmid 
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does not differ significantly from those of wild-type HIV-1, and it contains all the splice 
sites and recapitulates all splicing events of HIV-1 pre-mRNA in transfected HeLa cells 
or infected peripheral blood mononuclear cells. RT-PCR was then performed to analyze 
the mRNA level produced by splicing using the forward primer BSS 
(5′-GGCTTGCTGAAGCGCGCACGGCAAGAGG-3′; nt 700–727) and reverse 
primers SJ4.7A, which spans sites D4 and A7 
(5′-TTGGGAGGTGGGTTGCTTTGATAGAG-3′ ) to amplify all the 2 kb splicing 
isoforms encoding the viral proteins Nef, Rev, and Tat (Figure 3.15). 
Four candidate compounds, including compounds 5, D1, D2 and D3 were tested in the 
ex vivo splicing assay using the highest soluble concentration (10μM, 15μM, 50μM, 
7.5μM respectively). My results showed that while all four compounds inhibited HIV-1 
pre-mRNA splicing to some extent, compounds 5 and D3 were more effective (Figure 
3.16). This suggests the candidate compounds have inhibitory effects on HIV-1 splicing, 
however, their potencies were not consistent with the results obtained from in vitro 
kinase assays or SPR assays. Further experiments are required to determine the exact 
effect of these candidates on HIV-1 life cycle and their mechanisms of inhibition. 
On the other hand, based on our in vitro results, compound N7 is a very promising 
candidate that might be a true SRPK1-ASF/SF2 interaction inhibitor. Compound N7 
was tested ex vivo for its effect on HIV-1 splicing using different concentrations. Figure 
3.17 shows that the synthesis of all splicing products from the transfected cells treated 
with compound N7 was less efficient when compared to DMSO-treated cells. 
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Figure 3. 15 Schematic representation of HIV-1 pΔPSP plasmid and primer design for 
ex vivo splicing assay. pΔPSP plasmid, HIV-1 proviral genome deleted between 
nucleotides 1511 and 4550. Forward primer BSS 
(5′-GGCTTGCTGAAGCGCGCACGGCAAGAGG-3′; nt 700–727) and reverse 
primers SJ4.7A, which spans sites D4 and A7 








Figure 3. 16 Compounds 5, D1, D2 and D3 alter HIV alternative splicing. HEK 293 
cells transfected with the pΔPSP construct and EGFP were treated with DMSO or four 
select compounds (lanes 1–5, respectively). Multiple spliced products of HIV-1 RNA 
were amplified by RT-PCR using the oligonucleotide primers BSS and SJ4.7A. The 
PCR products were analyzed by polyacrylamide gel electrophoresis after normalization 
with GAPDH and EGFP. The intensities of the HIV-1 pre-mRNA splicing products 
decreased in the presence of compounds, suggesting the compounds had altered the 




 Figure 3. 17 Selective inhibition of HIV-1 RNA splicing ex vivo by natural compound 
N7. Experiment conditions are the same as in Figure 3.16. Compound N7 appears to 
inhibit the splicing of HIV-1 pre-mRNA in a dose-dependent manner. 
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 Furthermore, the inhibition effect of compound N7 was dose dependent. The 
inhibitory effect is particular obvious for the synthesis of the larger splicing isoforms, 
which were completely blocked with 35 μM of compound (Figure 3.17).  
This dose-dependent profile of splicing inhibition indicated that the natural 
compound N7 inhibits the usage of several 3’splice sites which are critically regulated 
by the binding of SR proteins, especially ASF/SF2. This result, together with our in 
vitro results, proved that by inhibiting the phosphorylation of ASF/SF2, it is possible to 
abrogate the pre-mRNA splicing of HIV-1. 
 
3.5 Cytotoxic effect of candidate compound on HeLa cells  
Since compound N7 appeared to be the sole inhibitor that blocks ASF/SF2 
phosphorylation by disrupting its interaction with SRPK1, as well as abrogating the 
splicing of HIV-1 mRNA, I determined to continue investigating the biological activity 
of this compound and its effect on HIV-1 pathogenic function. In order to determine 
cytotoxicity of natural compound and the suitable concentration for the following in 
vivo experiment, MTT assay was first preformed to test the effect of compound N7 on 
HeLa cells. HeLa cells were exposed to compound N7 with concentrations ranging from 
1 to 200 μM for 24 hours. Cell viability was then measured by an MTT assay and 
presented as a percentage of colorimetric absorbance derived from the 
compound-treated cells compared with that from the mock-treated cells (with 1% 
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Figure 3. 18 Cytotoxic effect of natural compound N7 on HeLa cells in MTT assay. 
Cytotoxicity of HeLa cells after natural compound exposure in different concentrations 
for 24 h. The viability is normalized with 1% DMSO. Cells remained viable in the 
presence of 50 M compound but started dying in the presence of higher concentration 
of compound. 
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 compound (Figure 3.18). The concentration at which the compound reduced the 
number of viable cells to 50% was around 100μM, confirming that the concentration 
being used in the ex vivo splicing assay did not induce toxicity to the cells. 
 
3.6 Nature compound alters ASF/SF2 localization 
To explore how inhibition of ASF/SF2 phosphorylation affects its biological 
function, we performed immunocytochemistry to test the localization of ASF/SF2 in the 
presence of either the natural compound or the vehicle control (DMSO). Previous 
studies have indicated that ASF/SF2 mainly localizes in the nucleus in various cell types, 
but the protein could also be found shuttling between the nucleus and cytoplasm. In 
addition, localization of ASF/SF2 is depended on its phosphorylation by different 
kinases. We hypothesized that any inhibition in the phosphorylation mechanism of 
SRPK1 might disturb the cellular distribution of the SR proteins in vivo, especially 
ASF/SF2.  
Wild-type myc-ASF/SF2 was transfected and overexpressed in HeLa cells and 
analyses for subcellular distribution by indirect immunofluorescence with anti-myc 
antibody. We observed that ASF/SF2 (wt) localized predominantly in the nucleus in the 
presence of the vehicle control DMSO as expected. However, myc-ASF/SF2 (wt) 
treated with 30 μM nature compound N7 was detected to diffuse in both nucleus and 
cytoplasm (Figure  3.19). Our result suggests that the natural compound N7 
successfully altered the localization of ASF/SF2. Since phosphorylation of the RS  
 86
 Figure 3. 19 The distribution of ASF/SF2 is altered by natural compound N7 in vivo. 
Indirect immunofluorescent staining of transfected HeLa cells using the anti-Myc 
antibody. Localization studies of Myc-ASF/SF2 (wt) show that ASF/SF2 are localized 
predominantly in the nucleus with the vehicle control (DMSO). The natural compound 
causes diffusion of ASF/SF2 in both of the nucleus and cytoplasm, suggesting it is no 
longer phosphorylated by SRPK1. 
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 domain is critical for nuclear import of ASF/SF2, this assay demonstrates that the 
natural compound might inhibit specific phosphorylation-dependent localization of 
ASF/SF2.
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Chapter Ⅳ: Discussion and Conclusion 
Our aim is to develop a novel class of SRPK1 inhibitors to interfere the binding 
between the SRPK1 and ASF/SF2 by blocking the docking groove of SRPK1 and inhibit 
the phosphorylation of ASF/SF2.  However, due to the high cost and long time required 
for drug discovery using conventional methods like high-throughput screening, we 
adopted computer-based drug screening method to identify potential candidates. 
We have designed a two-step screening approach which combined AutoDock 4 and 
AutoDock Vina for new inhibitor discovery. This approach takes the full advantages of 
two software, by which we saved much screening time as well as achieving more 
accurate results through two different algorithms. AutoDock Vina greatly speeded up 
the screening procedures, providing the chance to screen a much large database of small 
molecules. On the other hand, AutoDock 4 following AutoDock Vina helped to 
reconfirm the docking results of each compound and increased the accuracy of the 
molecular modeling simulation. 
 351,473 compounds from the natural products database of ZINC and the 
commercially available SPECS were firstly screened by AutoDock Vina and 2846 
compounds were selected with good binding affinity to SRPK1 docking groove. After 
rescreen of these 2846 candidates using AutoDock 4, 42 compounds ranked as the top 
candidates that have the highest binding affinities to SRPK1 in both programs were 
selected and purchased for further analysis. These candidates include 8 compounds 
from the natural products library and 34 compounds from the SPECS library. Among 
these 42 candidates, three compounds belonging to SPECS and one natural compound 
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were shown to inhibit the phosphorylation of ASF/SF2 by SRPK1 with potencies at 
micromolar concentrations. In particular, compound 5 and natural compound N7 were 
proven to be effective inhibitors. Based in this result, I further selected and purchase 3 
structural-related compounds of compound 5 to test their effects on SRPK1 activity. 
These three compounds also appeared to exert good inhibition effects on SRPK1. 
However, since our aim is to develop protein-protein binding inhibitors, we needed to 
confirm if the selected compounds block the protein-protein interaction. While 
compound 5 and its analogues could inhibit the phosphorylation of ASF/SF2 by SRPK1, 
they failed to block the kinase-substrate interaction effectively in our SRP assays. On 
the other hand, the natural compound N7 successfully inhibited the binding of ASF/SF2 
to SRPK1 with an IC50 around 250μM. This is inconsistent with the result obtained in 
the kinase activity assay, which showed that compound N7 could inhibit SRPK1 activity 
with an IC50 around 36μM. The reason for such inconsistency is unknown but it is 
possible that the effective concentrations of compound N7 in both assays are different. 
Since many compounds I have tested had limited solubility even in the presence of 5% 
DMSO, it is highly possible that some of the DMSO-dissolved compound N7 might 
have precipitated out from the solution phase under the different experimental 
conditions being used for the two assays, thus leading to large error in the calculation of 
IC50s. Further research is required to investigate the exact reason for the observed 
inconsistency. 
Another interesting observation is that while 5 of the selected candidate inhibitors, 
namely natural compound N7, compound 5, D1, D2 and D3 could inhibit SRPK1 to 
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some extent, they could not completely block the kinase activity. This could due the 
extensive amount of RS dipeptide repeats present in the RS domain of ASF/SF2. While 
SRPK1 has been shown to utilize its docking groove to restrict the phosphorylation of 
ASF/SF2 to the N-terminal half of its RS domain, it is unpreventable that some minor 
non-specific phosphorylation could have happened at the C-terminal half of ASF/SF2 RS 
domain since both chemical and physical properties of the two halves are highly similar. 
Furthermore, the kinase activity in vitro is not abrogated in the presence of the 
protein-protein interaction inhibitor. Therefore, even the inhibitors could block the 
docking groove of SRPK1 and prevent specific phosphorylation of the N-terminal RS 
domain of ASF/SF2, non-specific phosphorylation elsewhere could not be prevented. 
Moreover, alteration in phosphorylation state of ASF/SF2, but not necessarily complete 
inhibition of phosphorylation, could still abrogate ASF/SF2’s function in HIV-1 splicing. 
The predicted binding models of the candidate compounds to SRPK1 showed that 
the docked compounds form direct contracts with several amino acids within the 
docking groove of SRPK1 (Figure 4.1 and 4.2). Particularly, the top candidate 
compounds were predicted to interact with at least one of the docking groove residues 
D548, D564, E571, and K615 that are essential for substrate binding to the docking 
groove. However, we could not get promising results for some of the inhibitors in the 
binding competition assays. One explanation is that the candidate compounds might 
have bound to other region(s) outside of the intended docking site, resulting in 
nonspecific binding on the kinase and cause allosteric inhibition on the kinase. 
Alternately, they might have inhibit the kinase activity by binding to the ATP-binding 
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Figure 4. 1 Predicted binding model of compound 5 to SRPK1. The binding mode 
of compound 5 is shown. The SRPK1 structure is shown in blue. Sulfur, oxygen, or 
nitrogen atoms on the active compounds are indicated as yellow, red, or blue spheres, 









































































































































 cleft non-specfically. To investigate the real inhibition mechanism, further research 
like the resolution of the structure of SRPK1 in complex with the candidate compounds 
are required. 
The most promising candidate obtained in this project, natural compound N7, has 
been proven in vitro to inhibit the phosphorylation of ASF/SF2 by SRPK1 through the 
blocking of kinase-substrate interaction. The compound has also been shown to affect 
the localization of ASF/SF2 in vivo, likely due to an alteration of its phosphorylation 
state as we have proposed. Furthermore, it displayed a good dose-dependent inhibition 
profile of HIV-1 pre-mRNA splicing ex vivo. More importantly, natural compound N7 
also showed a promising effect in a syncytium reduction assays performed by our 
collaborators at the Kunming Institute of Zoology using HIV-1 virus infected human T 
cells (data not shown). Although the TI (therapeutic index) of natural compound N7 is 
above 11.866, which is much lower than the control drug AZT, this could serve as a lead 
for more potent HIV inhibitor. Therefore, while the detailed inhibition mechanism of 
this compound remains to be fully elucidated, my results present here strongly suggest 
that compound N7 could be a true hit and could be further developed into a novel HIV-1 
treatment that targets its splicing pathway.  
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